Medistim ASA (0OCD) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, everyone, and welcome to Medistim's fourth quarter and preliminary financial results for 2025 presentation. My name is Kari Krogstad and I'm joined with the CFO, Thomas Jakobsen. And we will go through this usual agenda, starting with the highlights. And I'm very pleased to be able to report a new record for sales in the quarter, reaching 182.3 million NOX in Q4. This means that we are continuing the high growth all through the year that we've seen in the first three quarters, ending with 20.6% growth in this fourth quarter. We can see that there is quite a small currency effect when we are comparing to the currency in the same quarter last year. But still adjusting for that, the total sales would be 21.7%. And we're seeing that our own products are doing really well and the sales is up 25%. And it is America's region that is really leading the way with 44.3% currency neutral growth. We also see that EMEA, Europe, Middle East and Africa has a very strong quarter, this fourth quarter being up 24.4%. Our Asia-Pacific region is down by 24.2%, and as we have consistently reported all through the year, we have to expect quarterly variations from Asia-Pacific, but we also expected to see a solid year, which we will show. The third-party products has small 2.2% growth in the quarter, but we know that they had a tremendous start and will finish the year very strong. Also, the operating profit is very strong, 42.3 million, up 63.8% from the same quarter last year. And I just want to mention that the EBIT margin of 23.2%, although being a lot higher than the margin that we reported in the same quarter last year, is impacted by an increase in IT infrastructure expenses of 5.8 million. So this obviously has a negative impact and actually this EBIT margin would have...